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Abstract
Background: Diuretics are recommended as initial treatment for hypertension. Several studies have
suggested suboptimal persistence and adherence to thiazide diuretic monotherapy; this study compared
patient persistence and adherence with hydrochlorothiazide (HCTZ) monotherapy to fixed-dose
combinations containing HCTZ.
Methods: Patients with at least one prescription claim during 2001 to 2003 for either HCTZ or one of
the following fixed-dose combinations: angiotensin-receptor blockers/HCTZ (ARB/HCTZ), angiotensin-
converting enzyme inhibitor/HCTZ (ACEI/HCTZ), or beta blockers/HCTZ (BB/HCTZ) were identified.
Patients were required to be continuously benefit-eligible six months pre- and one year post-index date,
and to have no prescription claims for any antihypertensive therapy six months prior to the index date.
Patients were followed for one year to assess persistence, medication possession ratio (MPR), adherence
(MPR >80%), and proportion of days covered (PDC) with initial antihypertensive therapy. Logistic
regression was used to calculate adjusted odds ratios for persistence, adherence and PDC, adjusted for
age, gender, business segment, RxRisk disease categories, average co-pay and concurrent cardiovascular-
related medication utilization.
Results: The study cohort consisted of 48,212 patients; 72.5% used HCTZ, 13.2% ACEI/HCTZ, 9.3%
ARB/HCTZ, and 5.0% BB/HCTZ. Mean age was 53.7 years and 66.5% were female. A significantly lower
proportion of patients using HCTZ (29.9%) remained persistent with therapy at 12 months compared with
ARB/HCTZ (52.6%; OR = 0.37, CI = 0.36, 0.38), ACEI/HCTZ (51.4%; OR = 0.38, CI = 0.37, 0.39), and BB/
HCTZ (51.9%; OR = 0.38, 0.37, 0.40). Similarly, PDC was lower for HCTZ patients (32.5%) as compared
to ARB/HCTZ (53.7%; OR = 0.39, CI = 0.37, 0.40), ACEI/HCTZ (50.9%; OR = 0.42, CI = 0.40, 0.43), and
BB/HCTZ (51.3%; OR = 0.44, CI 0.42, 0.45). MPR was also significantly lower for HCTZ patients as
compared to those using fixed-dose combination therapies.
Conclusion: Initiating HCTZ fixed-dose combination therapy with an ACEI, ARB, or BB was associated
with greater persistence and adherence as compared to HCTZ monotherapy. Further research is needed
to determine the relationship between improved persistence and adherence with blood pressure control.
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Background
Hypertension affects almost one in three American adults;
age-adjusted prevalence in 2005 was estimated at 33.6%
[1,2]. Only 37% of patients with hypertension, and only
slightly more than half (57%) of those receiving antihy-
pertensive treatment currently have their blood pressure
(BP) controlled [1]. The Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure published its seventh report (JNC 7) in
2003 [3]. JNC 7 included the recommendation of thiazide
diuretics, either alone or in combination with drugs from
other classes, as initial therapy treatment of most patients
with hypertension.
Patient persistence and adherence to prescribed antihy-
pertensive therapy is a key component of hypertension
management. Greater persistence with antihypertensive
therapy has been associated with lower rates of long-term
hypertension sequelae [4], as well lower health care
resource use [5-8] and hospitalization rates [6]. In usual-
practice settings, less than optimal persistence with anti-
hypertensive monotherapy regimens has been well docu-
mented [9-13]. Several studies have indicated that initial
monotherapy treatment with diuretics is associated with
poorer patient persistence, compared to angiotensin-con-
verting enzyme inhibitors (ACEI), angiotensin-receptor
blockers (ARB), and beta blockers (BB). [9,11,13]. Tolera-
bility and perceived side effects associated with antihyper-
tensive medications may play an important role in patient
motivation, and thus affect medication persistence [14].
Patients may complain of frequent urination upon initia-
tion of diuretic therapy, and diuretics have been associ-
ated with side effects such as weakness, fatigue,
palpitations, and electrolyte disturbances. Patients are
often prescribed a lower dose of diuretic when used in
combination therapy with an agent from another antihy-
pertensive class, and combination low-dose therapy has
been shown to increase BP-lowering efficacy and reduce
adverse side effects associated with higher-dose mono-
therapy regimens [15]. Thus, the addition of a medication
from another antihypertensive class to a diuretic may
attenuate the side effects often seen with diuretics when
used as monotherapy [15-17].
The purpose of this study was to compare patient persist-
ence and adherence to hydrochlorothiazide (HCTZ) mon-
otherapy versus fixed-dose combinations containing
HCTZ and an ACEI, ARB, or BB in a natural (non-clinical
trial) setting. This retrospective, longitudinal cohort study
employed administrative pharmacy claims data to exam-
ine drug utilization in patients previously naïve to antihy-
pertensive therapy who initiated therapy with HCTZ
monotherapy, or fixed-dose ACEI/HCTZ, ARB/HCTZ, or
BB/HCTZ.
Methods
This was a retrospective, population-based study which
employed a pharmacy claims database from MedImpact,
a large US pharmacy benefits manager (PBM) which
administers prescription benefits for about 27 million
persons across the US. Adult participants (≥ 18 years) were
eligible for study inclusion if they received ≥ 1 prescrip-
tion for HCTZ or fixed-dose combination ACEI/HCTZ,
ARB/HCTZ, or BB/HCTZ during the study identification
period of January 1, 2001 through December 31, 2003.
"Index drug" was defined as the first prescription therapy
filled within the identification period, and the "index
date" was defined as the date of the first index drug fill.
Participants were required to be continuously benefit-eli-
gible for at least 6 months preceding and 12 months sub-
sequent to the index date. Patients were required to have
no claims for any antihypertensive therapy during the 6
months prior to their index date.
Drug utilization was followed for 1 year subsequent to the
index date, and analyses were performed relative to the
specific index drug classes. Figure 1 includes definitions of
utilization metrics, including persistence, medication pos-
session ratio (MPR), adherence, proportion of days cov-
ered (PDC) and time to therapy discontinuation. For
index drug classification purposes, patients who received
prescription fills for antihypertensive medications in
addition to the study index medication on their study
index date were excluded.
RxRisk [18] methodology was used to identify the pres-
ence of other diseases. RxRisk identifies claims during the
6 months prior to the index date for medications used to
treat specific conditions to identify co-morbidities (e.g. a
pharmacy claim for an oral antidiabetic agent is used to
identify the presence of diabetes). RxRisk disease catego-
ries were used (e.g. diabetes yes/no) to describe patient
clinical characteristics, and for adjustment of statistical
comparisons for the presence of co-morbid conditions.
To control for potential physician's treatment selection
bias, a propensity score adjustment was performed. A
multinomial regression model was constructed to esti-
mate the probability of the observed treatment choice
based on patient characteristics, including patient age,
gender, RxRisk disease categories, and type of benefit cov-
erage (i.e., Commercial, Medicaid, Medicare, and self-
insured). The inverse of this probability, or propensity
score weight, was then used in study multivariable logistic
and linear regressions. For MPR, multiple variable linear
regression techniques were used in pairwise comparisons
of means adjusted for independent variables, which
included propensity weight, patient age, gender, RxRisk
disease categories, type of benefit coverage, average co-
pay, and concurrent cardiovascular-related medicationsBMC Family Practice 2008, 9:61 http://www.biomedcentral.com/1471-2296/9/61
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utilized (i.e., other antihypertensive drugs not equal to the
initial therapy subsequent to the index pharmacy claim
date; and digitalis, nitrates, antiplatelet agents and antihy-
perlipidemics). Pairwise multiple logistic regression was
used to calculate odds ratios to compare persistence,
adherence, and proportion of days covered (PDC),
adjusted for the same independent variables, using HCTZ
monotherapy as the reference group. Although these sta-
tistical methods were used to control for important varia-
bles, crude statistics are included in the text and the tables
for descriptive purposes, since statistical adjustment did
not appreciably alter any values.
Persistence was evaluated using multivariable survival
analysis techniques. Cox proportional hazards regression
was employed to calculate hazard ratios (HR) to compare
discontinuation for antihypertensive medications stud-
ied, adjusted for covariates. Discontinuation of therapy
with the index medication was modeled using HCTZ as
the referent. All analyses for this study were performed
using SAS version 9.1.3 (SAS Institute, Inc, Cary, NC).
Results
The final study population was comprised of 48,212
patients newly initiated on antihypertensive therapy.
Cohort descriptive characteristics are summarized in
Table 1. Overall, 67% were females and the mean age was
53.7 years. HCTZ users comprised 72.5% of the study
cohort, while 13.2% used ACEI/HCTZ, 9.3% ARB/HCTZ,
and 5.0% BB/HCTZ. HCTZ and BB/HCTZ patients were
generally younger than ACEI/HCTZ or ARB/HCTZ
patients. Patients receiving HCTZ were more likely to be
female than those utilizing fixed-dose combination ther-
apy. The proportion of cohort patients with cardiovascu-
lar-related conditions or diabetes was higher for ACEI/
HCTZ and ARB/HCTZ than for HCTZ or BB/HCTZ.
Unadjusted results for antihypertensive medication utili-
zation metrics are displayed in Table 2. Patients receiving
HCTZ had the lowest persistence (29.9%), compared to
52.6% for ARB/HCTZ, 51.9% for BB/HCTZ, and 51.4%
for ACEI/HCTZ. The MPR was highest for BB/HCTZ
(62.1%), followed by ARB/HCTZ (60.5%), ACEI/HCTZ
(58.3%), and HCTZ (44.5%). Adherence was lowest for
HCTZ patients (24.2%) and highest for BB/HCTZ
(43.9%). HCTZ patients had the lowest proportion of
Study utilization metrics and definitions Figure 1
Study utilization metrics and definitions.
Days to Therapy 
Discontinuation* 
 
The date of fill for the last prescription during the 12-month 
study follow-up period prior to therapy discontinuation*, minus 
the index fill date, plus the days’ supply of the last fill date.  For 
patients who did not discontinue therapy with the index 
medication class during the study period, this was measured as 
the last prescription fill date plus days’ supply of that 
prescription fill, minus the index fill date. 
Persistence 
 
 
At monthly intervals post-index fill date (i.e. month 2, 3, 4…) 
and for the 12-month study period overall, the percentage of 
individuals remaining on therapy who did not discontinue* 
therapy with the index class. 
Medication 
Possession Ratio 
(MPR)   
 
The sum of days’ supply for all fills of the index hypertension 
class during the follow-up period, divided by the duration of the 
follow-up period (365 days), multiplied by 100 to express as a 
percentage.   
 
Adherence  
 
 
The percentage of individuals having an MPR > 80%, and no 
occurrence of discontinuation*, of the index class of 
hypertension medication 
Proportion of Days 
Covered (PDC) at 
end of follow up         
 
The percentage of patients who possess index class 
medication on day 365 of follow up, considering the specific 
time of each fill dates and corresponding days’ supply. 
* Discontinuation is defined as ending therapy with the target medication class and not 
receiving a fill for the target medication within 60 days after exhausting the days supply 
from the prior prescription claim. BMC Family Practice 2008, 9:61 http://www.biomedcentral.com/1471-2296/9/61
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days covered (32.5%), and time to therapy discontinua-
tion was longest for ARB/HCTZ patients (240.1 ± 140.3
days).
Adjusted odds ratios for persistence, adherence, and days
covered are found in Table 3. Compared to all fixed-dose
combination therapy users, HCTZ patients were signifi-
cantly (p < 0.01, all comparisons) less likely to be persist-
ent, adherent, and to have medication "on hand" at the
end of the study period. Patients receiving HCTZ were
approximately 63% less likely to be persistent compared
to ARB/HCTZ patients, 62% less likely to be persistent
than ACEI/HCTZ patients, and 61% less likely to be per-
sistent than BB/HCTZ patients. Similarly, HCTZ patients
were 60%, 54%, and 50% less likely to be adherent as
compared to BB/HCTZ, ARB/HCTZ, and ACEI/HCTZ
patients, respectively. Odds ratios for days' covered indi-
cated that HCTZ users were 61%, 59%, and 56% less
Table 1: Study cohort descriptive characteristics (N = 48,212)
Initial anti-hypertensive therapy
Characteristics HCTZ (N = 34,934, 72.5%) ARB/HCTZ 
(N = 4,469, 9.3%)
ACEI/HCTZ 
(N = 6,388, 13.2%)
BB/HCTZ 
(N = 2,421, 5.0%)
Mean age in years ± SD 53.6 ± 15.3 54.6 ± 13.8 54.3 ± 13.9 52.2 ± 13.8
Age in categories
18 – 44 (%) 10,296 (29.5) 1,006 (22.5) 1,486 (23.3) 712 (29.4)
45 – 54 (%) 9,769 (28.0) 1,457 (32.6) 2,021 (31.6) 780 (32.2)
55 – 64 (%) 6,423 (18.4) 1,006 (22.5) 1,469 (23.0) 505 (20.9)
65 – 74 (%) 4,500 (12.9) 570 (12.8) 824 (12.9) 256 (10.6)
75 – 84 (%) 2,925 (8.4) 327 (7.3) 443 (6.9) 115 (4.8)
85 and above (%) 1,021 (2.9) 103 (2.3) 145 (2.3) 53 (2.2)
Frequency female (%) 24,495 (70.1) 2,573 (57.6) 3,629 (56.8) 1,356 (56.0)
RxRiska, b
Behavioral Health 6,413 (18.4) 653 (14.6) 810 (12.7) 332 (13.7)
Cardiovascular 
Conditions
2,012 (5.8) 435 (9.7) 874 (13.7) 128 (5.3)
Gastric acid disorder, 
IBS
2,768 (7.9) 250 (5.6) 351 (5.5) 147 (6.1)
Asthma, Allergic Rhinitis 2,590 (7.4) 196 (4.4) 301 (4.7) 79 (3.3)
Diabetes 843 (2.4) 147 (3.3) 281 (4.4) 23 (1.0)
Thyroid Disease 2,193 (6.3) 230 (5.1) 321 (5.0) 108 (4.5)
Rheumatoid Arthritis, 
Gout
1,273 (3.6) 120 (2.7) 171 (2.7) 50 (2.1)
Primary market segment
HMO 24,562 (70.3) 2,644 (59.2) 4,656 (72.9) 1,631 (67.4)
Medicaid 4,103 (11.8) 125 (2.8) 300 (4.7) 112 (4.6)
Medicare 2,285 (6.5) 227 (5.1) 355 (5.6) 122 (5.0)
Self-insured 3,984 (11.4) 1,473 (33.0) 1,077 (16.9) 556 (23.0)
Average copay ($)c 5.2 ± 4.2 22.8 ± 19.0 14.0 ± 13.0 9.2 ± 8.7
a The 49 RxRisk categories were consolidated into 21 categories of which the top 7 most prevalent groups (3% threshold) are presented here. 
Behavioral health = anxiety and tension, bipolar, depression, psychotic illness, attention deficit disorder; Cardiovascular conditions: Cardiac disease, 
coronary & peripheral vascular disease, heart disease, hypertension (does not include the target medications, digitalis, nitrates, anti-platelet agents 
or anti-hyperlipemic agents); Gastrointestinal (GI) disorders = Gastric acid disorder, irritable bowel syndrome
b Limited to antihypertensive medications of the same class as the index drug
Table 2: Unadjusted antihypertensive persistence and adherence
Outcome measures HCTZ ARB/HCTZ ACEI/HCTZ BB/HCTZ
Persistence (%) 29.9 52.6 51.4 51.9
Adherence (%) 24.2 39.2 38.8 43.9
PDCa at end of follow-up (%) 32.5 53.7 50.9 51.3
MPRb ± SD 44.5 ± 34.5 60.5 ± 32.7 58.3 ± 34.2 62.1 ± 34.1
Days to therapy discontinuation ± SD 164.5 ± 141.8 240.1 ± 140.3 235.9 ± 140.8 238.2 ± 140.9
aPDC denotes proportion of days covered at the end of the follow-up period. The percentage of patients who possess index class medication on 
day 365 of follow-up period.
bMPR denotes medication possession ratio.BMC Family Practice 2008, 9:61 http://www.biomedcentral.com/1471-2296/9/61
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likely to have medication on hand at the end of the study
as compared to ARB/HCTZ, ACEI/HCTZ, and BB/HCTZ
patients, respectively. Comparisons for MPR (Table 3)
also revealed that HCTZ patients had lower adjusted
mean MPR as compared to BB/HCTZ (difference = -17.0,
p < 0.0001), ARB/HCTZ (difference = -16.6, p < 0.0001),
and ACEI/HCTZ (difference = -12.9, p < 0.0001).
Cox proportional hazards model results are included in
Table 4. Patients receiving HCTZ were more likely to dis-
continue the index medication class as compared to users
of ACEI/HCTZ, ARB/HCTZ, and BB/HCTZ, adjusted for
demographic and clinical covariates. Cardiovascular-
related conditions and patient copay were not significant
predictors of therapy discontinuation in the proportional
Table 3: Outcome measures – adjusted pairwise comparison of HCTZ monotherapy versus each fixed-dose combination therapy
HCTZ fixed-dose combination therapy
Outcome measures ARB/HCTZ ACEI/HCTZ BB/HCTZ
Persistence (Odds Ratio, 95% CI) 0.369a
(0.356, 0.383)
0.380a
(0.368, 0.393)
0.382a
(0.370, 0.395)
Adherence (Odds Ratio, 95% CI) 0.457a
(0.440, 0.475)
0.495a
(0.478, 0.513)
0.398a
(0.385, 0.412)
PDC at end of follow-up period (Odds Ratio, 95% CI) 0.388a
(0.374, 0.403)
0.415a
(0.402, 0.429)
0.435a
(0.421, 0.449)
MPR (HCTZ vs. fixed-dose) 44.4 vs 61.0
Δ = -16.6b
44.6 vs 57.5
Δ = -12.9b
44.5 vs 61.5
Δ = -17.0b
a Significant difference in outcome measures between pairwise comparison with HCTZ users at p < 0.05.
b p < 0.0001
Table 4: Results of Cox proportional hazards model for therapy discontinuation
Study population (N = 48,212)
Variable Hazards ratio p-value
Age 0.989 <.0001*
Female 1.048 0.0002*
RxRisk categoriesa
Anxiety and Tension, Bipolar Disorder, Depression, Psychotic Illness, ADD 1.079 <.0001*
Asthma, Allergic Rhinitis 1.031 0.1891
Cardiac Disease, Coronary & Peripheral Vascular Disease, Heart Disease, Hypertensionb 0.973 0.2432
Gastric acid disorder, IBS 1.004 0.8477
Rheumatoid Arthritis, Gout 1.147 <.0001*
Thyroid Disease 0.951 0.0426*
Diabetes 1.158 <.0001*
Business Type
HMO N/A N/A
Medicaid 1.339 <.0001*
Medicare 1.451 <.0001*
Self 1.056 0.0013*
Concomitant Other CVD-related Medications Used
Digitalis 1.138 0.0086*
Nitrates 1.224 <.0001*
Antiplatelet Medications 1.097 0.0502
Antihyperlipidemic Medications 0.797 <.0001*
Average copayc 1.001 0.3831
Target medication classesd
ARB/HCTZ 0.529 <.0001*
ACEI/HCTZ 0.536 <.0001*
BB/HCTZ 0.532 <.0001*
* Significant p-value
a RxRisk categories shown in this table include the 7 most frequent disease states in the study cohort. All RxRisk disease categories were included 
in the model.
b This RxRisk category does not include the target medications, digitalis, nitrates, antiplatelet medications or antihyperlipidemics.
c Limited to HTN medications of the same class as the index drug.
d Reference Medication Class = HCTZBMC Family Practice 2008, 9:61 http://www.biomedcentral.com/1471-2296/9/61
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hazards model. An increased hazard of therapy discontin-
uation was observed for Medicaid and Medicare patients
as compared to managed care patients, and for patients
with diabetes.
Discussion
Our retrospective study found that the combination of
another antihypertensive medication with HCTZ via
fixed-dose combination therapy was associated with bet-
ter patient persistence and adherence as compared to
HCTZ monotherapy. HCTZ patients were 61–63% less
likely to be persistent, and 50–60% less likely to be adher-
ent, than patients who initiated antihypertensive therapy
with fixed-dose ACEI/HCTZ, ARB/HCTZ, or BB/HCTZ
therapy. Patients were more likely to stay on fixed-dose
combinations longer than monotherapy, as mean time to
therapy discontinuation was, on average, two and a half
months longer for fixed-dose combinations than for mon-
otherapy. To our knowledge, the current study is the first
to compare persistence with HCTZ monotherapy to fixed-
dose HCTZ combination therapy in a "usual care" setting
in the US.
A few other studies have used retrospective methods to
evaluate combination therapy in "usual-care" settings out-
side of the US. Van Wijk et al, in a recent community-
based retrospective study using pharmacy dispensing
records in the Netherlands, studied 2325 previously naïve
patients who newly initiated antihypertensive therapy
with a ACEI, BB, calcium channel blocker (CCB), or diu-
retic [19]. Only 39% of patients used antihypertensive
therapy consistently during 10 years of follow-up. More
patients who initiated therapy with diuretics and BB dis-
continued compared to those who started with a CCB or
ACEI. In this study, comparing patients who initiated with
diuretics, those who started with fixed-dose combination
therapy were 70% more likely to be persistent with ther-
apy (OR 0.29; 95% CI 0.14–0.54).
Another recent study comparing utilization for antihyper-
tensive monotherapy versus fixed-dose combination ther-
apy used a Canadian database, and found that during the
first 6 months after treatment was initiated, persistence
declined to 75%; at the end of 3 years, only 55% were per-
sistent [20]. During the first year of follow-up, compared
to diuretic monotherapy, patients prescribed other anti-
hypertensive classes or fixed-dose combination therapy
(HR 0.71; 95% CI 0.67 to 0.75) were found to have higher
persistence [20]. Other studies comparing monotherapy
regimens conducted in naturalistic settings have consist-
ently found poorer compliance and/or persistence for diu-
retics as compared to other antihypertensive therapeutic
classes [11-13,21,22]. Conlin and colleagues [9] followed
patients from a large pharmacy benefits manager (PBM)
and demonstrated that at 4 years post-therapy initiation,
only 16% of diuretic patients were persistent, compared
to 61% of ARB, 47% of ACEI, 41% of CCB, and 35% of BB
patients.
Improving patient adherence and persistence with antihy-
pertensive therapy may have a beneficial effect on blood
pressure control. One recent retrospective study of 840
patients using antihypertensive monotherapy assessed the
relationship between medication compliance and blood
pressure control (<140/90 mmHg or < 130/85 mmHg for
diabetic hypertensive patients) [23]. Patients received
monotherapy with an ACEI (27%), or CCB (22%), BB
(20%), or diuretic (11%) and were classified as having
high (80–100%), medium (50–79%), or low (<50%)
medication compliance. High-compliance patients were
45% more likely to achieve blood pressure control than
those with medium or low compliance after controlling
for age, gender, and comorbidities.
Differences between antihypertensive drug regimens for
patient medication adherence and persistence may have
cost implications. Increased healthcare expenditures for
nonadherent patients with hypertension in usual-care set-
tings have been well documented [5-8]. In one study,
Medicaid patients with an interruption of antihyperten-
sive therapy consumed extra healthcare costs of $873/
patient during the first year [5]. Another study of both
MCO and traditional fee-for-service patients from a large
PBM found that better compliance with antihypertensive
therapy was associated with a decreased risk of hospitali-
zation and, thus, lower medical costs [6]. Addressing
patient noncompliance with antihypertensive medication
can thus play an important role in managing the costs of
patient care for MCOs and other healthcare providers.
Retrospective analyses of administrative databases can
provide information about patient behavior in a natural-
istic setting that is difficult to assess in clinical trials, but it
is important to note some study limitations. Since defini-
tions of adherence and persistence may be expected to dif-
fer somewhat between studies, comparisons of
medication utilization results across studies should be
interpreted cautiously. As medical claims were unavaila-
ble to confirm hypertension diagnosis, some of the
patients included may not have had a diagnosis of hyper-
tension, and may have been prescribed a study medica-
tion for an unrelated diagnosis. This may have particularly
influenced patient selection for BB/HCTZ users, as this
combination has multiple indications and may be used
more frequently in patients with stable angina or acute
coronary syndromes. Drug utilization metrics were meas-
ured by prescription refill patterns and not actual drug
taken by the patient; however, other studies have sup-
ported the evaluation of pharmacy claims data for such
purposes [24,25]. Propensity score weighting was used inBMC Family Practice 2008, 9:61 http://www.biomedcentral.com/1471-2296/9/61
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statistical analyses to control for selection bias, but it is
possible that factors that were not available for analysis
may have played a role in physician treatment selection.
Since patient BP was not available for analysis, patients
prescribed HCTZ in combination with a drug from
another antihypertensive class may have had a higher
baseline BP than those prescribed HCTZ alone; this infor-
mation was unavailable for inclusion in the propensity
score adjustment and may have influenced our study's
results. It could be hypothesized that patients prescribed
HCTZ alone may be "healthier" patients than those pre-
scribed HCTZ in combination. While analysis of the prev-
alence of comorbid conditions between treatment groups
suggests that this may be somewhat true for HCTZ mono-
therapy patients as compared to ARB/HCTZ and ACEI/
HCTZ patients, frequency of cardiovascular diagnoses and
diabetes were similar for HCTZ and BB/HCTZ patients, yet
persistence and adherence for BB/HCTZ patients was
much greater than for HCTZ patients. Statistical analyses
were employed to control for such differences in patient
co-morbidity and demographic characteristics, and signif-
icant differences in therapy discontinuation rates per-
sisted. Since we identified patients using a 6-month prior
eligibility criteria, it is possible that some patients may
have discontinued previous AHY therapy prior to the 6
months or received another AHY therapy while a member
of another health plan. It is possible that a patient who
discontinued a study medication did so based on physi-
cian instructions, and this would have been incorrectly
classified as non-persistence and may have influenced
study results. Finally, our study included only fixed-dose
combinations with HCTZ and excluded free combination
regimens. Other studies have demonstrated improved
persistence with fixed-dose antihypertensive combination
regimens as compared to free combinations [26]; there-
fore, some of the persistence advantages found in our
study of fixed-dose combinations may not be evident
when using free combination regimens.
This study sought to evaluate patient utilization of HCTZ
monotherapy as compared to HCTZ used in combination
in patients new to antihypertensive therapy. Our findings
are not meant to imply that all patients prescribed HCTZ
as monotherapy are candidates for initial combination
antihypertensive therapy; important prescriber and
patient clinical factors play a role in the choice of initial
antihypertensive therapy. However, our study provides
additional information regarding the use of these regi-
mens in a non-clinical trial setting, and when interpreted
in the context of other literature suggesting poor patient
adherence and persistence with HCTZ monotherapy ver-
sus monotherapy with other antihypertensive classes, pro-
vides important information to prescribers of
antihypertensive medication.
Conclusion
In a naturalistic, non-clinical trial setting, our study sug-
gested that patients who initiated new antihypertensive
therapy with HCTZ in a fixed-dose combination with an
ACEI, ARB, or BB may be more persistent than patients
who initiated antihypertensive therapy with HCTZ alone.
HCTZ patients were also less likely to be adherent as com-
pared to fixed-dose combination patients, and to stay on
therapy an average of 2.5 months less during the first year
than patients using fixed-dose combinations. While addi-
tional research is needed to evaluate the impact of
improved persistence and adherence with blood pressure
control across practice settings, improving patient adher-
ence and persistence with antihypertensive medication is
an important approach to improving blood pressure con-
trol in the US.
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